Pharmaceutical production is marked by the need for massive investments in innovation and the manufacture of new products, in addition to uncertainties associated with the effectiveness of drugs under development.

Seeking to overcome the inherent difficulties of the sector, important movements have taken place in Brazil in recent years, following a trend of consolidation of large companies.

Today's bulletin highlights the main strategic motivations for M&As in the pharmaceutical sector, providing examples of transactions involving Brazilian companies.